Redx Pharma Plc announced the appointment of Dr. Joseph Anderson as a Non-Executive Director on the Board of Directors of the Company (the ?Board?), effective immediately. Dr. Anderson will join the Board as a representative of Sofinnova Crossover I SLP (?Sofinnova?), one of the Company's major shareholders. As previously announced on 3 July 2023, Dr. Anderson's appointment was subject to due diligence and other appointment processes which have now completed.

Dr. Joseph Anderson, aged 64, holds or has previously held the following directorships: Current directorships: F2g Ltd. and Autolus Therapeutics Plc; Former directorships: Arix Bioscience Plc.